Perioperative Cimetidine Administration Enhances Tumor Infiltration Lymphocytes and HLA-DR Expression in Colorectal Cancer~*  

围手术期应用西米替丁对结直肠癌TIL浸润及HLA-DR表达的影响

作　　者：陈爱军 李雁[1] 杨国粱[1] 袁宏银[1] 白德骄[1] 

机构地区：[1]武汉大学中南医院肿瘤科,430071

出　　处：《The Chinese-German Journal of Clinical Oncology》2006年第1期49-53,共5页中德临床肿瘤学杂志（英文版）

基　　金：This project was supported by New-Century Excellent Talents Supporting Program of the Ministry of Education (NCET-04-0669).

摘　　要：Objective： It has been shown in our previous study that cimetidine （CIM） can boost the hosts＇ cellular immunity in patients with gastrointestinal cancer. This study was conducted to evaluate CIM＇s effects on tumor infiltrating lymphocytes （TIL） and HLA-DR expression in tumor stroma in colorectal cancer （CRC）, so as to investigate its role in local immune response at the tumor site in CRC. Methods： Forty-nine CRC patients were randomized into treatment group of 25 patients who took CIM 7 days before curative surgery till the operation day, and control group of 24 patients who received similar treatment except for CIM intervention. TIL responses and HLA-DR expression were studied on tumor tissues taken before and after surgical resection. Results： The percentage of significant TIL response was increased from 32% （8/25） to 76% （19/25） （P〈0.005） in the CIM treatment group, whereas there were no significant changes in TIL response in the control group [25% （6/24） at recruitment vs. 33% （8/24） at operation, P〉0.50]. Moreover, the percentages of HLA-DR expression were increased from 36% （9/25） to 72% （18/25） in the CIM treatment group, but there were no significant differences in HLA-DR expression in the control group [41.7% （10/24） before resection vs 45.8% （11/24） after resection, P〉0.50]. Conclusion： CIM used before surgery might promote TIL responses and increase the HLA-DR expression in stroma cells in CRC patients, leading to enhanced host immunity against tumor.

关 键 词：IMMUNOMODULATION CIMETIDINE colorectal cancer HLA-DR 

分 类 号：R735.3[医药卫生—肿瘤]